Cargando…
Disclosing the potential impact of placebo controls in antidepressant trials
BACKGROUND: Although placebo-control clinical trials that withhold effective treatments can be permissible, how best to inform participants of the placebo design has received little attention. AIMS: To determine the effect of disclosing quantitative outcome estimates of individual treatment v. enter...
Autores principales: | Chen, Stephanie C., McCullumsmith, Cheryl, Kim, Scott Y. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal College of Psychiatrists
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995553/ https://www.ncbi.nlm.nih.gov/pubmed/27703715 http://dx.doi.org/10.1192/bjpo.bp.115.000109 |
Ejemplares similares
-
12.1 CELL-SUBTYPE SPECIFIC BIOENERGETIC DEFECTS IN SCHIZOPHRENIA
por: Sullivan, Courtney, et al.
Publicado: (2018) -
SSRIs: Applications in inflammatory lung disease and implications for COVID‐19
por: Meikle, Claire Kyung Sun, et al.
Publicado: (2021) -
Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials
por: Trinquart, Ludovic, et al.
Publicado: (2012) -
32.2 ABNORMALITIES OF SYNAPTIC PROTEOMES IN SCHIZOPHRENIA
por: Funk, Adam, et al.
Publicado: (2018) -
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
por: Creeden, Justin Fortune, et al.
Publicado: (2021)